Conference Coverage

Revascularization in paraplegics best performed with PCI


 

AT THE 2018 CRT MEETING


When evaluated with propensity scoring, the differences in outcomes between those with or without paraplegia/quadriplegia were more modest, but MACE rates after CABG remained significantly higher (8.4% vs. 3.5%; P = .02). In contrast, the difference in MACE rates after propensity matching was no longer significantly higher in the paraplegia/quadriplegia group treated with PCI (4.4% vs. 2.0%; P = .46).

When CABG was compared to PCI among those with paraplegia/quadriplegia, the rate of in-hospital mortality was almost four times higher (9.5% vs. 2.5; P less than.01). Paraplegic/quadriplegic patients treated with CABG also had longer lengths of hospital stay and incurred higher treatment costs, according to Dr. Dai.

The moderator of the session at which these data were presented, Scott Schurmer, MD, chief of cardiology at Texas Tech Health Sciences Center, Lubbock, cautioned about the limitations of propensity scoring. He also suggested that PCI, based on concern for potential comorbidities in patients with paraplegia and quadriplegia, would likely be the choice of many physicians even without these data.

Dr. Dai reported no financial relationships to disclose.

SOURCE: Dai X. CRT 2018.

Pages

Recommended Reading

VIDEO: No short-term link found between PPIs, myocardial infarction
MDedge Cardiology
Overweight and obese individuals face greater cardiovascular morbidity
MDedge Cardiology
Abruptio placenta brings increased cardiovascular risk – and soon
MDedge Cardiology
Sex-triggered sudden cardiac arrest extremely rare
MDedge Cardiology
200 cardiovascular drugs now in development
MDedge Cardiology
Young diabetics are at sevenfold increased risk of sudden cardiac death
MDedge Cardiology
ACC Late-Breaking Clinical Trial sessions preview for day 1
MDedge Cardiology
ACC Day 2: Late-Breaking Clinical Trial highlights
MDedge Cardiology
Heart attacks soar in young IBD patients
MDedge Cardiology
ACC Day 3: Finishing strong in Late-Breaking Clinical Trial Sessions
MDedge Cardiology